Benzodiazepines are widely used in clinics and for recreational purposes, but will lead to addiction in vulnerable individuals. Addictive drugs increase the levels of dopamine and also trigger long-lasting synaptic adaptations in the mesolimbic reward system that ultimately may induce the pathological behaviour. The neural basis for the addictive nature of benzodiazepines, however, remains elusive. Here we show that benzodiazepines increase firing of dopamine neurons of the ventral tegmental area through the positive modulation of GABA(A) (gamma-aminobutyric acid type A) receptors in nearby interneurons. Such disinhibition, which relies on alpha1-containing GABA(A) receptors expressed in these cells, triggers drug-evoked synaptic plasticity in excitatory afferents onto dopamine neurons and underlies drug reinforcement. Taken together, our data provide evidence that benzodiazepines share defining pharmacological features of addictive drugs through cell-type-specific expression of alpha1-containing GABA(A) receptors in the ventral tegmental area. The data also indicate that subunit-selective benzodiazepines sparing alpha1 may be devoid of addiction liability.
Benzodiazepines are widely used in clinics and for recreational purposes, but will lead to addiction in vulnerable individuals. Addictive drugs increase the levels of dopamine and also trigger long-lasting synaptic adaptations in the mesolimbic reward system that ultimately may induce the pathological behaviour. The neural basis for the addictive nature of benzodiazepines, however, remains elusive. Here we show that benzodiazepines increase firing of dopamine neurons of the ventral tegmental area through the positive modulation of GABA(A) (gamma-aminobutyric acid type A) receptors in nearby interneurons. Such disinhibition, which relies on alpha1-containing GABA(A) receptors expressed in these cells, triggers drug-evoked synaptic plasticity in excitatory afferents onto dopamine neurons and underlies drug reinforcement. Taken together, our data provide evidence that benzodiazepines share defining pharmacological features of addictive drugs through cell-type-specific expression of alpha1-containing GABA(A) receptors in the ventral tegmental area. The data also indicate that subunit-selective benzodiazepines sparing alpha1 may be devoid of addiction liability.
Addictive drugs can be classified into three groups, according to the cellular
mechanism through which they increase mesolimbic dopamine (DA)1. Opioids, cannabinoids and the club drug γ-hydroxy
butyrate reduce release from inhibitory afferents onto DA neurons, through their
respective G-protein coupled receptors on GABA neurons. These substances activate pre-
and postsynaptic receptors, indirectly increasing the firing rate of DA neurons, a
mechanism defined as disinhibition. Nicotine, as a member of the second group, directly
depolarizes DA neurons by activating α4β2-containing acetylcholine
receptors, while the third group targets DA transporters (e.g. cocaine and
amphetamines). It remains unclear whether these mechanisms can account for the addiction
liability of benzodiazepines (BDZs)2, which are
positive modulators of GABAAR function.In addition to increasing mesolimbic DA, another common feature to all addictive
drugs studied so far is that they trigger adaptive synaptic plasticity in the ventral
tregmental area (VTA)3. Hours after the initial
exposure, excitatory afferents onto DA neurons of the VTA are strengthened, in part by
the insertion of GluR2-lacking AMPARs4,5
6. To test whether a similar mechanism is elicited
by BDZs, we examined whether a single injection of a BDZ would, in addition to an
increase of AMPA/NMDA ratio7, also cause a change
in slope of the current-voltage (iv)-curve of evoked excitatory postsynaptic currents
(EPSCs). Such rectification reflects the presence of GluR2-lacking AMPARs, which are
calcium permeable and blocked by polyamines at positive potentials.
BDZ-evoked plasticity in dopamine neurons
In slices obtained 24 h after the i.p. injection of midazolam (MDZ), diazepam
(DZ), or flunitrazepam (FZ), the rectification index (RI =
EPSC−65 mV/EPSC+35 mV) was significantly
higher than in slices from saline-injected controls (Fig. 1a and Supplementary Fig. 2). Similar rectification was measured after an
injection of morphine (Mor), a member of the class of drugs that cause disinhibition
of DA neurons8. The BDZ antagonist flumazenil
(Flu) blocked rectification when co-injected with MDZ but was without effect when
co-injected with a control saline solution (Fig.
2 and Supplementary
Fig. 2). The adaptive plasticity induced by systemic BDZs was also
observed 24 h after local application of MDZ into the VTA by stereotactic injection
(0.5 μl of a 8 mg/ml solution over 10 minutes; Fig. 1b). Thus, BDZ-dependent effects on VTA circuitry are sufficient to
induce this cellular hallmark of addictive drugs.
Figure 1
BDZ-evoked synaptic plasticity is abolished in α1(H101R) mutant
mice
a, Top panel; normalized AMPAR-EPSCs obtained at -65, 0 and +35 mV in
slices from WT mice i.p. injected with saline, MDZ (0.5 mg/kg) or Mor (15
mg/kg) 24 h prior to sacrifice. Middle panel; corresponding iv-curves.
Bottom panel; bar graphs represent group data for the RI. F(2;21)
= 9.08. b, AMPAR-EPSCs, iv-curves and RI (top, middle and bottom
panel, respectively) observed when ACSF or MDZ were injected into the VTA in
WT mice. t(11) = 5.43. c, Similar experiments performed
with α1(H101R) mice. Note that Mor induces a rectification that is
similar in WT and mutant mice. F(2;16) = 17.88. d,
Similar experiments performed with α1(H101R) mice when MDZ was
injected intra-VTA. n = 6-10.
Figure 2
Synaptic plasticity evoked by α1-subunit selective
compounds
a, Normalized AMPAR-EPSCs obtained at -65, 0 and +35 mV in slices
from WT mice injected with ZOL (5 mg/kg i.p.), L-838 417 (10 mg/kg i.p.) and
MDZ together with Flu (5 mg/kg), 24 h prior to sacrifice. b, Corresponding
iv-curves. c, Bar graphs representing group data for the RI.
F(2,19) = 28.97. n = 6-8.
BDZs bind to GABAARs at the interface between α and
γ subunits9 in a subunit-dependent
manner. GABA neurons in many parts of the brain express the α1 subunit
isoform10, while midbrain DA neurons lack
α1 but express α2, α3, and α4 subunit isoforms11. Thus, the addictive potential of BDZs might
rely on the potentiation of α1-containing GABAARs, which would
selectively inhibit GABA neurons and lead to disinhibition of DA neurons. To test
this idea, we examined whether MDZ (i.e. a rapidly acting, non-selective BDZ with a
very strong brain uptake12) has an effect in
mice with a point mutation (H101R) in the α1 subunit that disrupts the BDZ
binding site13. In α1(H101R) mice,
MDZ no longer had an effect on the RI of AMPAR EPSCs in DA neurons (Fig. 1c). This was not due to a general loss of adaptive
plasticity, as morphine still caused a strong rectification. Stereotactic injections
of MDZ into the VTA also failed to elicit rectifying AMPAR-mediated EPSCs in
α1(H101R) mice (Fig. 1d). Furthermore,
MDZ increased the AMPA/NMDA ratio, while control injections of ACSF were without
effect in either genotype (Supplementary Fig. 3).We next used pharmacological tools to confirm the involvement of α1.
Zolpidem (ZOL) is a non-classical BDZs selective for α1-containing
GABAARs14 while the
experimental compound L-838 417 does not modulate receptors that contain
α115. We therefore tested whether
ZOL and L-838 417 could evoke synaptic plasticity in DA neurons. We found that a
single injection of ZOL led to rectifying AMPAR-mediated EPSCs, while L-838 417 did
not affect the iv-curve (Fig. 2). Taken
together with the results in α1(H101R) mice described above, we conclude
that BDZ-evoked synaptic plasticity depends on α1-containing
GABAARs within the VTA.
Cell type-specific expression of α1
To identify α1-expressing cells in the VTA, we next carried out
immunohistochemical staining for tyrosine hydroxylase (TH) and the α1
subunit isoform in GAD-67 GFP mice (Fig. 3a).
These experiments confirmed that α1 was expressed mainly in GFP-positive
neurons, but not in TH-positive DA neurons. Quantifications revealed that
81% of the GABA neurons contained the α1 subunit isoform, while this
was the case only in 7% of the DA neurons (Inset Fig. 3a). We also observed α1-staining that could
neither be associated to TH-positive nor GAD67-GFP-expressing cells. This may
reflect the pool of the so-called tertiary cells that are neither DA- nor
GABA-neurons16,17 or be due to detectability limits in fine
processes.
Figure 3
α1 is selectively expressed in GABA neurons of the VTA
a, Immunohistochemical staining for tyrosine hydroxylase (TH, red) and
༟1 (blue) in VTA slices of GAD67-GFP (green) knock-in mice. Concentric
pie charts represent the fraction of α1-positive cells (inner
segment), and quantification of the two cell types (outer segment, n
= 4 mice). Overlap between inner and outer segments represents
colocalization. b, Example trace of mIPSCs recordings in GABA and DA neurons
obtained in slices from WT mice. c, Representative averaged mIPSC trace from
a GABA and a DA neuron. The overlay shows the difference in kinetics when
the two currents are normalized to the average mIPSC peak amplitude. d,
Box-plots represent group data for charge transfer and amplitude of mIPSCs
obtained from GABA and DA neurons in slices from WT mice. t(75)
= 7.55 and t(75) = 3.16, respectively. (n
= 25-48). e, Representative average traces of mIPSCs before (solid
line) and after (dotted line) application of MDZ (100 nM) in slices from WT
and α1(H101R) mice. f, Corresponding box-plots representing group
data for relative increase in charge transfer and frequency after MDZ
bath-application. t(14) = 3.06 and t(14)
= 3.23. n = 6-10.
To assess the functional consequences of this cell type-specific isoform
expression for inhibitory transmission, we characterized miniature inhibitory
postsynaptic currents (mIPSCs) in the presence of the glutamate receptor blocker
kynurenic acid to isolate GABAAR-mediated currents (Fig. 3b, c). On average mIPSCs in GABA neurons were slower
and bigger than those in DA neurons, leading to a significantly larger charge
transfer in the former (Fig. 3d). This
difference was of similar magnitude in WT and α1(H101R) mice (Supplementary Fig. 4), in
line with previous reports13 that baseline
transmission in mutant mice is normal. Moreover, the frequency of mIPSCs as well as
the multiplicity factor (See methods for detailed description, supplementary Fig. 4c) were similar in
GABA and DA neurons in both genotypes. Although this approach has its
limitations18, it suggests that the
numbers of inhibitory synapses are in the same range in the two cell types. To
further confirm that synapses on GABA neurons express α1-containing
GABAARs, we tested for effects of MDZ on charge transfer and
frequency of mIPSCs in WT and α1(H101R) mice. In DA neurons, MDZ
significantly increased the charge transfer and decreased the mIPSC frequency in
both genotypes. In GABA neurons, MDZ increased the charge transfer and decreased
mIPSC frequency in slices from WT mice, but was without effect on mIPSCs recorded in
slices from α1(H101R) mice (Fig. 3e, f
and supplementary Fig. 5a).
As expected, MDZ had no effect on mIPSC amplitude in either cell type or
genotype19 (Supplementary Fig. 5b). The observation
that the mIPSC frequency is reduced by BDZs except in GABA neurons of
α1(H101) mice is surprising at first, but could reflect presynaptic
GABAARs. In fact such receptors have been described in the VTA,
which, upon activation reduce the release probability20.Since DA neurons express a set of many subunits11 the identification of the molecular composition of the
GABAAR is difficult. Most DA neurons actually express the α3
subunit isoform (96%, supplementary Fig. 6). Importantly the majority of GABA neurons do not
express the α3 subunit isoform (70%) even though significant
heterogeneity was observed. In heterologous expressed systems, currents of
α1-containing receptors are smaller than those of α3-containing
ones21. This however does not apply to DA
neurons in the VTA since in α3 KO mice currents are reduced only by
50%22. Our results establish that
in α1(H101R) mice endogenous GABAA-mediated synaptic transmission
is normal, while the positive modulation of MDZ was abolished in GABA neurons,
because the α1 subunit isoform is selectively expressed in these cells.
Cellular determinants of disinhibition
In WT mice, mIPSCs in both GABA and DA neurons were enhanced by BDZs.
However, when BDZs are administered whilst transmission is intact, the extent of
current amplification in DA neurons depends on the frequency of synaptic events,
which originate in the interneurons upstream. We therefore monitored the effect of
MDZ on spike-driven, spontaneous IPSCs (sIPSC) in DA neurons (Fig. 4). Although, the charge transfer of sIPSCs on
average increased after MDZ (in line with the mIPSC data), there was a strong
reduction of the frequency of spike-driven events in DA neurons (Supplementary Fig. 7). As a result,
when we integrated the charge transfer of sIPSCs over time before and after
application of MDZ (relative total current), we found a significant decrease (Fig. 4b). Because interneurons are efficiently
inhibited by MDZ, fewer spikes are generated, strongly decreasing the number of
sIPSC, an effect that predominates over the MDZ amplification of the individual
event. In α1(H101R) mice, in contrast, we observed an increased total
current in DA neurons because the GABA neurons were insensitive to MDZ. In summary,
in the WT mice, MDZ led to a net decrease of the total inhibitory current in DA
neurons, which could be sufficient to cause their disinhibition (see supplementary Fig. 1 for
schematics).
Figure 4
The total current generated by sIPSC in DA neurons is decreased by
MDZ
a, Example trace of sIPSCs recordings in GABA and DA neurons obtained before
and after application of MDZ in slices from WT and α1(H101R) mice.
sIPSCs were abolished with picrotoxin (PTX, 100 μM, not shown). b,
Group data for the relative increase in the overall charge transfer (1 min)
after MDZ bath-application. Note that in WT mice the total current in DA
neurons decreases with MDZ application while in α1(H101R) mice there
is an increase. GABA/WT vs GABA/α1(H101R) t(9) =
6.39, DA/WT vs DA/α1(H101R) t(15) = 5.50. n
= 6-7.
We therefore tested the effect of MDZ on the firing rate of DA neurons in
the VTA by performing extracellular single unit recordings in vivo.
When the drug was injected into the tail vein of WT mice, we recorded a significant
increase of the firing rate that was reversed by Flu (Fig. 5a, e, g). In stark contrast, no such disinhibition could be
observed in α1(H101R) mice (Fig. 5b, e,
g). In line with a disinhibition scenario, the data in the DA neurons
were mirrored by the observations in GABA neurons. MDZ caused an inhibition of the
spontaneous firing rates, at times leading to complete spike suppression (Fig. 5c, f, g). In α1(H101R) miceMDZ did
not significantly affect firing in GABA neurons (Fig.
5d, f, g). The specificity of these findings are further demonstrated by
the observation that, in mice where a different α subunit isoform had been
mutated (α3(H126R) mice)23, MDZ
caused an increase in the firing rate of DA neurons comparable to WT mice (Supplementary Fig. 8). The
magnitude of increase in the firing rate was inversely related to the basal firing
rate, which further suggests a disinhibition scenario (Fig. 5e). Moreover, in α1(H101R) mice disinhibition of DA
neurons was observed with Mor, an effect that was also inversely correlated to the
basal firing rate (Fig. 5h). Although
anesthesia may modify the overall distribution of firing rates and therefore the
magnitude of the disinhibition, the mean basal firing rates observed here were
comparable to values recorded in freely moving animals24,25.
Figure 5
Opposing effects of MDZ on in vivo firing rates of DA
and GABA neurons
a, Representative extracellular single unit recording of a DA neuron during
the i.v. injection of MDZ (0.5 mg/kg) in WT mice. Corresponding firing
frequency plot (lower panel; Flu 1 mg/kg). b, Same experiment in
α1(H101R) mice. c, Same experiment as in a) while monitoring a GABA
neuron. d, Response of a GABA neuron to MDZ in an α1(H101R) mouse.
White bars indicate time windows of traces shown above. e, Normalized firing
rate of DA neurons in response to MDZ as a function of the basal activity in
WT and α1(H101R) mice. WT/ α1(H101R) : F(2;23)
= 10.63. f, Corresponding plot with the results obtained in GABA
neurons. Notice that 3 out of 5 neurons were completely silenced, which
precluded fitting. g, Box-plots representing group data for relative change
in firing rate. WT DA/ α1(H101R) DA: t(23) =
2.70, WT GABA/ α1(H101R) GABA t(12) = 4.60. h,
Normalized firing rate in response to i.v. injection of Mor (5 mg/kg) as a
function of the basal activity in WT and α1(H101R) mice. Solid
lines: regression curves; shaded area: 95% confidence intervals. n
= 5-15.
Self-administration of midazolam
The results above demonstrate that α1-containing GABAAR
mediate the increase of mesolimbic DA in response to BDZs. Furthermore DA
antagonists can reduce self-administration of and preference to these drugs26,27.
We therefore tested the impact of the α1 subunit isoform on oral
self-administration of MDZ, by offering the mice a free choice of two drinking
solutions (Fig. 6a). During the first three
days the two bottles contained water. Sucrose was then added in both bottles to mask
any bitter taste. This led to an increase of the overall consumption, but no
particular preference. Finally, MDZ was added to one of the two bottles. During the
test period with MDZ, the total consumption did not change in either genotype (Fig 6b). A preference for the MDZ solution
developed rapidly in WT mice, but not α1(H101R) mice (Fig. 6c, d). WT mice drank between 0.8-1.1 mg/kg/24h of
MDZ, which corresponds to a pharmacological dose. Two control experiments were
carried out using a similar protocol. First, we offered α1(H101R) mice a
choice between water and a sucrose solution. Both WT and mutant mice developed a
strong preference for sucrose, indicating that α1(H101R) mice are not
generally deficient in reward reinforcement (Supplementary Fig. 9). We also tested
whether α3(H126R) mice, where MDZ caused a normal disinhibition of DA
neurons (Supplementary Fig.
8) would develop a preference for MDZ, which was indeed the case (Supplementary Fig. 10).
Although BDZs, particularly MDZ, may enhance taste perception28, this is unlikely to influence the interpretation of
these data, as several studies have shown that BDZ-mediated taste enhancement is
independent of α1-containing GABAAR29,30.
Figure 6
Oral self-administration of MDZ
a, Protocol for behavioral experiment. b, Total consumption successively with
water, sucrose, and MDZ (0.005 mg/ml) + sucrose (4 %) in WT
mice (black) and α1(H101R) mice (red). Note that WT and
α1(H101R) mice drink similar amounts of liquids. c, Relative MDZ
consumption in WT and α1(H101R) mice. d, Corresponding box plots for
relative average consumption of MDZ at days indicated. n = 12-18
mice in 4-6 cages. F(3;16) = 5.39
Discussion
Based on our data, we propose that BDZs increase DA levels through
disinhibition, similar to opioids, cannabinoids, and GHB. This disinhibition is
dependent on the BDZ binding site on α1-containing GABAARs in the
VTA. The net effect of BDZs on the VTA circuit is dominated by the role of
α1-containing GABAARs, which is supported by the following three
observations. First, GABAARs mediated quantal transmission is stronger in
GABA neurons than in DA neurons, as evidenced by the larger charge transfer of
mIPSCs (Fig. 3d). Second, GABA neurons have a
higher input resistance than DA neurons17,
allowing the same charge transfer to more effectively change the membrane potential
of GABA neurons than DA neurons. Finally, the BDZ-dependent enhancement of each IPSC
on DA neurons causes little inhibition of DA neuron activity because GABA neurons
fall silent and no longer generate those IPSCs. Our model could also apply to
earlier work probing the effect of the GABAAR agonist muscimol31. When administered directly into the VTA,
muscimol causes an increase of DA levels in the nucleus accumbens32. This effect only occurs at low doses, which led to
the conclusion that the effect is mediated indirectly on non-DA neurons33,34.
This inverse dose-dependence may be due to the fact that muscimol, unlike BDZs, is
not a positive modulator but an agonist. In line with this interpretation, muscimol
at high concentrations in fact inhibits DA neurons35.The implication of α1 in the addictive effect of BDZs is surprising
since the clinically available compound ZOL is selective for this subunit and has
been claimed to carry a low risk for addiction36. However this optimistic view contrasts with the observation that ZOL
is readily self-administered37 and the
clinical reality. Our data with the subunit isoform-selective compounds also show
that ZOL triggers drug-evoked plasticity and suggest that α1-sparing
compounds may be promising candidates in the search for BDZs devoid of addiction
liability. Since α1-containing GABAA receptors outside the VTA
mediate additional effects such as seizure control, sedation and anterograde
amnesia38, α1-sparing compounds
will certainly not be suitable for all indications. The dissociation between
anxiolysis, mainly α2-mediated23, and
addiction however seems possible in principle. This is particularly appealing since
high anxiety levels suggest increased vulnerability for addiction39.In conclusion, our work unravels the molecular basis of the defining
pharmacological features that BDZs share with addictive drugs, which we believe will
be key for designing new BDZs with lower addiction liability. However, we note that
increased levels of mesolimbic dopamine are necessary for addiction, but not
sufficient on their own. Recent studies suggest that early drug-evoked plasticity in
the VTA may facilitate addiction by gating more enduring forms of adaptations in
target regions of the mesolimbic system, which would represent the eventual locus
underlying long-term addictive behaviors40,41. Coinciding factors of
vulnerability, either in the initial events in the VTA or subsequent events in
mesolimbic targets, may ultimately explain individual variations in susceptibility
to addiction, both for BDZs and for other drugs42.
Methods Summary
Horizontal slices of the midbrain (250 μm) were prepared as
previously described43 from C57BL/6 mice,
Pitx3-GFP knock-in mice44, GAD67-GFP
Δneo mice45 and α1(H101R)
knock-in mice13 24 h after i.p. or intra-VTA
(ML ±0.8, AP -2.4, DV -4.4 mm from Bregma) injections of different BDZs.
AMPAR-mediated EPSCs were recorded in presence of d-APV and picrotoxin. mIPSCs were
recorded in presence of kynurenic acid (2 mM) and tetrodotoxin (TTX, 500 nM).
In vivo extracellular single unit recordings of DA neurons in
the VTA (ML: -1.2, AP: -3.2, DV -4 to 4.5 mm from the bregma) were carried out in
WT, α1(H101R) and α3(H126R)23
knock-in mice. Drugs were delivered through the tail vein. Immunofluorescence with a
guinea pig antibody against the α1 or α3 subunit, a mouse antibody
against TH, and a rabbit antibody against eGFP was performed as previously
described10 in GAD67-GFP Δneo
mice. For the oral self-administration of MDZ, mice were housed with free access to
two bottles containing either MDZ in sucrose or sucrose alone. Grouped data are
expressed as means ± SEM. For statistical comparisons the one-way Anova,
Bonferroni matched or the paired Student's t-tests were used. The levels of
significance are indicated as follows: * P<0.05, **
P<0.01, *** P<0.001.
Authors: Emanuela Argilli; David R Sibley; Robert C Malenka; Pamela M England; Antonello Bonci Journal: J Neurosci Date: 2008-09-10 Impact factor: 6.167
Authors: Gwenaël Labouèbe; Marta Lomazzi; Hans G Cruz; Cyril Creton; Rafael Luján; Meng Li; Yuchio Yanagawa; Kunihiko Obata; Masahiko Watanabe; Kevin Wickman; Stephanie B Boyer; Paul A Slesinger; Christian Lüscher Journal: Nat Neurosci Date: 2007-10-28 Impact factor: 24.884
Authors: Ana P L Abdala; Mathias Dutschmann; John M Bissonnette; Julian F R Paton Journal: Proc Natl Acad Sci U S A Date: 2010-10-04 Impact factor: 11.205
Authors: Claire L Padgett; Arnaud L Lalive; Kelly R Tan; Miho Terunuma; Michaelanne B Munoz; Menelas N Pangalos; José Martínez-Hernández; Masahiko Watanabe; Stephen J Moss; Rafael Luján; Christian Lüscher; Paul A Slesinger Journal: Neuron Date: 2012-03-08 Impact factor: 17.173
Authors: A Leslie Morrow; C J Malanga; Eric W Fish; Buddy J Whitman; Jeff F DiBerto; J Elliott Robinson Journal: Psychopharmacology (Berl) Date: 2014-05-09 Impact factor: 4.530